CN114680339A - Nutritional supplement for improving muscle attenuation and delaying senescence and application thereof - Google Patents
Nutritional supplement for improving muscle attenuation and delaying senescence and application thereof Download PDFInfo
- Publication number
- CN114680339A CN114680339A CN202210378872.6A CN202210378872A CN114680339A CN 114680339 A CN114680339 A CN 114680339A CN 202210378872 A CN202210378872 A CN 202210378872A CN 114680339 A CN114680339 A CN 114680339A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- nutritional supplement
- powder
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 44
- 210000003205 muscle Anatomy 0.000 title claims abstract description 13
- 230000009758 senescence Effects 0.000 title abstract description 4
- 239000000843 powder Substances 0.000 claims abstract description 54
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 229940088594 vitamin Drugs 0.000 claims abstract description 30
- 229930003231 vitamin Natural products 0.000 claims abstract description 30
- 235000013343 vitamin Nutrition 0.000 claims abstract description 30
- 239000011782 vitamin Substances 0.000 claims abstract description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 23
- 235000015097 nutrients Nutrition 0.000 claims abstract description 19
- 240000008042 Zea mays Species 0.000 claims abstract description 16
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 16
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 16
- 235000005822 corn Nutrition 0.000 claims abstract description 16
- 230000032683 aging Effects 0.000 claims abstract description 14
- 235000013336 milk Nutrition 0.000 claims abstract description 13
- 239000008267 milk Substances 0.000 claims abstract description 13
- 210000004080 milk Anatomy 0.000 claims abstract description 13
- 108010084695 Pea Proteins Proteins 0.000 claims abstract description 11
- 235000019702 pea protein Nutrition 0.000 claims abstract description 11
- 210000002966 serum Anatomy 0.000 claims abstract description 11
- 244000068988 Glycine max Species 0.000 claims abstract description 9
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 9
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 9
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 8
- 235000010755 mineral Nutrition 0.000 claims abstract description 8
- 239000011707 mineral Substances 0.000 claims abstract description 8
- 108010088751 Albumins Proteins 0.000 claims abstract description 7
- 102000009027 Albumins Human genes 0.000 claims abstract description 7
- 108010074051 C-Reactive Protein Proteins 0.000 claims abstract description 7
- 102100032752 C-reactive protein Human genes 0.000 claims abstract description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 7
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000036541 health Effects 0.000 claims abstract description 6
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 claims abstract description 6
- 235000019143 vitamin K2 Nutrition 0.000 claims abstract description 6
- 239000011728 vitamin K2 Substances 0.000 claims abstract description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 25
- 230000006870 function Effects 0.000 claims description 21
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 11
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 9
- 229960000304 folic acid Drugs 0.000 claims description 9
- 235000019152 folic acid Nutrition 0.000 claims description 9
- 239000011724 folic acid Substances 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 229930003316 Vitamin D Natural products 0.000 claims description 8
- 235000013322 soy milk Nutrition 0.000 claims description 8
- 235000019166 vitamin D Nutrition 0.000 claims description 8
- 239000011710 vitamin D Substances 0.000 claims description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 8
- 229940046008 vitamin d Drugs 0.000 claims description 8
- 235000013325 dietary fiber Nutrition 0.000 claims description 7
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 239000003765 sweetening agent Substances 0.000 claims description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 239000001506 calcium phosphate Substances 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 6
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 6
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 6
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 6
- 229920002752 Konjac Polymers 0.000 claims description 5
- 235000013312 flour Nutrition 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 239000011787 zinc oxide Substances 0.000 claims description 5
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 4
- 244000185386 Thladiantha grosvenorii Species 0.000 claims description 4
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims description 4
- 241000209140 Triticum Species 0.000 claims description 4
- 235000021307 Triticum Nutrition 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 208000001076 sarcopenia Diseases 0.000 claims description 4
- 239000011781 sodium selenite Substances 0.000 claims description 4
- 229940013618 stevioside Drugs 0.000 claims description 4
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019202 steviosides Nutrition 0.000 claims description 4
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 4
- 235000008939 whole milk Nutrition 0.000 claims description 4
- 102000011632 Caseins Human genes 0.000 claims description 3
- 108010076119 Caseins Proteins 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 3
- 108010071390 Serum Albumin Proteins 0.000 claims description 3
- 102000007562 Serum Albumin Human genes 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 3
- 239000011706 ferric diphosphate Substances 0.000 claims description 3
- 235000007144 ferric diphosphate Nutrition 0.000 claims description 3
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 claims description 3
- 229940036404 ferric pyrophosphate Drugs 0.000 claims description 3
- 230000001976 improved effect Effects 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 229940080237 sodium caseinate Drugs 0.000 claims description 3
- 235000019982 sodium hexametaphosphate Nutrition 0.000 claims description 3
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 229960001471 sodium selenite Drugs 0.000 claims description 3
- 235000015921 sodium selenite Nutrition 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 3
- 235000019801 trisodium phosphate Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 235000005152 nicotinamide Nutrition 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 27
- 235000018102 proteins Nutrition 0.000 abstract description 16
- 102000004169 proteins and genes Human genes 0.000 abstract description 16
- 108090000623 proteins and genes Proteins 0.000 abstract description 16
- 239000000126 substance Substances 0.000 abstract description 10
- 235000001014 amino acid Nutrition 0.000 abstract description 9
- 150000001413 amino acids Chemical class 0.000 abstract description 9
- 235000016709 nutrition Nutrition 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
- 238000011156 evaluation Methods 0.000 abstract description 4
- 208000037976 chronic inflammation Diseases 0.000 abstract description 3
- 230000006020 chronic inflammation Effects 0.000 abstract description 3
- 230000004220 muscle function Effects 0.000 abstract description 3
- 235000004252 protein component Nutrition 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 235000013305 food Nutrition 0.000 description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 230000004060 metabolic process Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000003647 oxidation Effects 0.000 description 10
- 238000007254 oxidation reaction Methods 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- -1 steroid compound Chemical class 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 230000003920 cognitive function Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 229930003779 Vitamin B12 Natural products 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- 235000019163 vitamin B12 Nutrition 0.000 description 6
- 239000011715 vitamin B12 Substances 0.000 description 6
- 235000019165 vitamin E Nutrition 0.000 description 6
- 239000011709 vitamin E Substances 0.000 description 6
- 229940046009 vitamin E Drugs 0.000 description 6
- 229940011671 vitamin b6 Drugs 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 244000228451 Stevia rebaudiana Species 0.000 description 5
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 5
- 229930003451 Vitamin B1 Natural products 0.000 description 5
- 239000005515 coenzyme Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000035790 physiological processes and functions Effects 0.000 description 5
- 229960003495 thiamine Drugs 0.000 description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 5
- 235000010374 vitamin B1 Nutrition 0.000 description 5
- 239000011691 vitamin B1 Substances 0.000 description 5
- 235000019158 vitamin B6 Nutrition 0.000 description 5
- 239000011726 vitamin B6 Substances 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 244000247812 Amorphophallus rivieri Species 0.000 description 4
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000252 konjac Substances 0.000 description 4
- 235000010485 konjac Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- XWCYDHJOKKGVHC-UHFFFAOYSA-N Vitamin A2 Chemical compound OCC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C XWCYDHJOKKGVHC-UHFFFAOYSA-N 0.000 description 3
- 229930003471 Vitamin B2 Natural products 0.000 description 3
- 239000012670 alkaline solution Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000003863 physical function Effects 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 229930003802 tocotrienol Natural products 0.000 description 3
- 239000011731 tocotrienol Substances 0.000 description 3
- 235000019148 tocotrienols Nutrition 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 235000019164 vitamin B2 Nutrition 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- 235000005282 vitamin D3 Nutrition 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- VQKFNUFAXTZWDK-UHFFFAOYSA-N 2-Methylfuran Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 2
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 2
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000010632 Transcription Factor Activity Effects 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000037354 amino acid metabolism Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 2
- 239000011615 dehydroascorbic acid Substances 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- GJQWCDSAOUMKSE-STHAYSLISA-N 2,3-diketogulonic acid Chemical compound OC[C@H](O)[C@@H](O)C(=O)C(=O)C(O)=O GJQWCDSAOUMKSE-STHAYSLISA-N 0.000 description 1
- BYVKCQBOHJQWIO-UHFFFAOYSA-N 2-ethoxyethyl propanoate Chemical compound CCOCCOC(=O)CC BYVKCQBOHJQWIO-UHFFFAOYSA-N 0.000 description 1
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 1
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 description 1
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 description 1
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 description 1
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 229930000083 3-dehydroretinol Natural products 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004906 Biotin deficiency Diseases 0.000 description 1
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 102100025014 E3 ubiquitin-protein ligase TRIM63 Human genes 0.000 description 1
- 101710164910 E3 ubiquitin-protein ligase TRIM63 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 229910003424 Na2SeO3 Inorganic materials 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010040639 Sick sinus syndrome Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 201000000839 Vitamin K Deficiency Bleeding Diseases 0.000 description 1
- 206010047634 Vitamin K deficiency Diseases 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000019601 food appearance Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000007166 healthy aging Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 201000010930 hyperostosis Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000020162 malted milk drink Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000007084 physiological dysfunction Effects 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940091252 sodium supplement Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 208000016794 vitamin K deficiency hemorrhagic disease Diseases 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
- 235000019144 δ-tocotrienol Nutrition 0.000 description 1
- 239000011729 δ-tocotrienol Substances 0.000 description 1
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/29—Mineral substances, e.g. mineral oils or clays
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention provides a nutritional supplement for improving muscle attenuation and delaying senescence and application thereof, the nutritional supplement is designed aiming at the physiological characteristics and nutritional requirements of old people and is rich in protein components such as easily absorbed amino acids, peptides, high-quality protein and the like, and the nutritional supplement of various vitamins and mineral substances comprises a nutrient mixture, fermented pea protein peptide powder, corn oligopeptide powder, vitamin K2 and a soybean milk powder composition. The nutritional supplement provided by the invention can obviously improve the walking speed (important evaluation indexes of muscle function attenuation and aging) of the old, effectively improve the levels of serum 25(OH) D and albumin, reduce the concentration of serum hypersensitive C reactive protein, realize the reduction of the level of in vivo chronic inflammation, has an ideal effect of improving the muscle attenuation of the old, improve the independent living capacity and the living quality of the old, delay aging and prolong the health life.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to a nutritional supplement for improving muscle attenuation and delaying senescence of old people and application thereof.
Background
The deterioration of physical functions accompanying the increase of age seriously affects the quality of life of the elderly, and has become an important issue to cope with the social aging crisis. In order to implement the national innovation-driven development strategy, actively deal with the challenge brought by the aging of the population to the development of the economic society and promote the healthy aging, researchers should design the nutritional supplement for the old according to the physiological characteristics and nutritional requirements of the old so as to prevent the serious diseases such as the asthenia of the old and improve the life quality of the old. The related products appearing at present have unsatisfactory effects and poor pertinence.
Disclosure of Invention
In view of the above, the present invention provides a nutritional supplement for improving the physical functions of the elderly to solve the above problems. The nutritional supplement can obviously improve the walking speed (important evaluation indexes of muscle function attenuation and aging) of the old, effectively improve the levels of serum 25(OH) D and albumin, reduce the concentration of serum hypersensitive C reactive protein, has ideal effect of improving the muscle attenuation of the old, improves the independent living capacity and the living quality of the old, delays aging and prolongs the health life.
In order to achieve the purpose, the technical scheme of the invention is realized as follows:
a nutrient mixture comprises the following components in parts by weight: 0.18-0.35 part of vitamin mixture, 0.65-1.15 parts of mineral and 0.03-0.05 part of auxiliary material.
Further, the vitamin mixture comprises the following components in parts by weight: 0.004-0.008 parts of vitamin A3255(XHC), 0.006-0.009 parts of vitamin D100(XHC), 0.01-0.03 parts of vitamin E (50%), 0.001-0.003 parts of vitamin B1 (hydrochloric acid), 0.01-0.03 parts of vitamin B2 (10%), 0.04-0.08 parts of vitamin B6 (5%), 0.002-0.004 parts of vitamin B12 (0.1%), 0.1-0.15 parts of vitamin C, 0.008-0.012 parts of nicotinamide, 0.0015-0.003 parts of folic acid (10%), and 0.003-0.005 parts of biotin (1%).
Further, the mineral comprises the following components in parts by weight: 0.06-0.1 part of ferric pyrophosphate (11%), 0.008-0.012 part of zinc oxide, 0.015-0.02 part of sodium selenite (0.5%), and 0.6-1 part of tricalcium phosphate (superfine).
Further, the auxiliary material is maltodextrin.
Wherein vitamin A is a fat-soluble vitamin, organic compound, and has chemical formula of C20H30O is stable to heat, acid and alkali and is easily oxidized, and ultraviolet rays can promote the oxidative damage of the O. Vitamin A includes A1 and A2, A1 is retinol. Vitamin A2, 3-dehydroretinol, has a physiological activity of 40% of vitamin A1. Vitamin a has a wide range of important physiological functions in the human body, and in summary, mainly comprises visual sense, regulation of cell proliferation and differentiation, intercellular information exchange and immune response, and the deficiency of vitamin a causes physiological dysfunction and pathological changes. It can be used for strengthening food, dairy products and liquid food, and has functions of improving vision, cell differentiation and embryo development, and also has effects of immunity, taste, hearing, and appetite.
Vitamin D is a fat-soluble vitamin, a steroid compound, and 25- (OH) D is the predominant form of vitamin D present in the blood. Vitamin D mainly comprises vitamin D2 and vitamin D3, while vitamin D3 is most abundant in the body and plays an important physiological function. Vitamin D3 is converted in the liver to 25-hydroxyvitamin D3[25- (OH) D ]3]And subsequently converted to active 1, 25-dihydroxyvitamin D in the kidney3[1,25-(OH)2D3]。1,25-(OH)2D3Is the main active form of vitamin D in the body. Can promote the absorption of calcium and phosphorus by intestinal tract; mobilize bone calcium and promote the kidney to reabsorb calcium and phosphorus.
Vitamin E is a fat-soluble vitamin, which includes four tocopherols and four tocotrienols, and is an antioxidant. Vitamin E includes two classes of 8 compounds, namely, tocopherol and tocotrienol, namely, alpha, beta, gamma, delta tocopherol and alpha, beta, gamma, delta tocotrienol, and alpha-tocopherol is the most abundant and most active form of vitamin E distributed most widely in nature. Vitamin E has antioxidant effect. The activity of the tocotrienol is certain when the substituents are different, but the activity of the tocopherol is obviously reduced. Vitamin E has effects in resisting oxidation, resisting atherosclerosis, enhancing immunity, protecting nervous system and skeletal muscle, and improving embryonic development and reproduction.
Vitamin B1 was the first water-soluble vitamin purified by humans, chemically named 3- [ (4-amino-2-methyl-5-pyrimidinyl) -methyl ] -5-2-hydroxyethyl) -4-methylthiazolium chloride in the form of a white crystalline powder. It is slightly smelly, bitter in taste and deliquescent. Melting point 248 ℃, readily soluble in water, slightly soluble in ethanol, insoluble in ether and benzene. Vitamin B1 has effects in maintaining normal sugar metabolism and nerve conduction. The content of vitamin B1 in yeast is the most in nature. Can be synthesized from 2-methylfuran, vinyl nitrile and the like or synthesized from beta-ethoxyethyl propionate, ethyl formate and the like. The vitamin B1 can construct coenzyme and maintain normal metabolism in vivo; inhibiting cholinesterase activity, and promoting gastrointestinal motility; and has certain effect on nervous tissues.
Vitamin B2 is a water-soluble vitamin, but slightly soluble in water, with a solubility of 12mg/100mL at 27.5 ℃. Soluble in sodium chloride solution, easily soluble in dilute sodium hydroxide solution, easily soluble in alkaline solution, and stable in strong acid solution. Heat resistance and oxidation resistance. Light and uv radiation cause irreversible decomposition. The main physiological role of vitamin B2 is to promote metabolism as a coenzyme. Riboflavin is combined with phosphoric acid and a molecule of protein to form the flavoenzyme. This class of enzymes, also called dehydrogenases, is important for a very mediated transfer of hydrogen atoms important for the metabolism of sugars, lipids and amino acids. It is an essential factor for the growth of many animals and microorganisms. Participate in vivo biological oxidation and energy generation; FDA and FMN are involved in the conversion of tryptophan to nicotinic acid and vitamin B6 to pyridoxal phosphate as coenzymes, respectively; FDA is used as coenzyme of glutathione reductase, participates in an antioxidant defense system in vivo, and maintains the concentration of reduced glutathione; is involved in drug metabolism.
Vitamin B6 is colorless crystal, is easily soluble in water and ethanol, is stable in acid solution, is easily destroyed in alkaline solution, and has heat resistance to pyridoxine, pyridoxal and pyridoxamine. Vitamin B6 is rich in yeast, liver, grain, meat, fish, egg, bean and peanut. Vitamin B6 is a component of some coenzymes in human body, participates in various metabolic reactions, and especially has close relation with amino acid metabolism. Regulating immune function, reducing chronic diseases, improving nervous system, and participating in various metabolic processes, regulating lipid metabolism, regulating hormone, etc.
Vitamin B12 is a polycyclic compound containing 3-valent cobalt, with 4 reduced pyrrole rings linked together to become 1 corrin macrocycle (similar to porphyrin), the only metal-element-containing vitamin. The vitamin B12 is red crystal powder, has no smell and taste, is slightly soluble in water and ethanol, is most stable under the condition of pH 4.5-5.0 and weak acid, and can be decomposed in strong acid (pH <2) or alkaline solution to a certain extent when being heated. Higher animals and plants cannot produce vitamin B12, and vitamin B12 in nature is synthesized by microorganisms. Vitamin B12 is the only vitamin that needs the help of intestinal secretions (endogenous factors) to be absorbed, and is involved in the production of bone marrow red blood cells, prevention of pernicious anemia, and prevention of damage to the cerebral nerves. Can promote the biosynthesis of protein; protecting the transfer and storage of folic acid in cells.
Vitamin C is a polyhydroxy compound of the formula C6H8O6. The structure of the compound is similar to that of glucose, and two adjacent enol-type hydroxyl groups at the 2 nd and 3 rd positions in the molecule are easy to dissociate to release H +, so that the compound has the property of acid and is also called L-ascorbic acid. Vitamin C has strong reducibility and is easily oxidized into dehydrovitamin C, but the reaction is reversible, and ascorbic acid and dehydroascorbic acid have the same physiological function, but if the dehydroascorbic acid is further hydrolyzed to generate diketogulonic acid, the reaction is irreversible and the physiological effect is completely lost. Promoting collagen synthesis, neurotransmitter synthesis, detoxification, preventing cancer, scavenging free radicals, promoting antibody formation and iron absorption, etc.
Niacinamide is an amide compound of nicotinic acid. A crystalline powder that is white; no or almost no odor, bitter taste; it is slightly hygroscopic. It is soluble in water or ethanol, and soluble in glycerol. The traditional Chinese medicine composition is mainly used for preventing and treating pellagra, stomatitis, glossitis, sick sinus syndrome, atrioventricular block and the like in clinic. Promoting the processes of biological oxidation and tissue metabolism in vivo, protecting cardiovascular system, etc.
Folic acid is a water-soluble vitamin with the molecular formula of C19H19N7O6. The green leaf is named because it is rich in pteroylglutamic acid. There are several forms of parent compound which occur in nature and which are a combination of 3 components of pteridine, p-aminobenzoic acid and glutamic acid. Folic acid contains 1 or more glutamyl groups and most naturally occurring folic acid is in the form of polyglutamic acid. The biologically active form of folic acid is tetrahydrofolic acid. Folic acid is yellow crystals, slightly soluble in water, but its sodium salt is very soluble in water. Is insoluble in ethanol. It is easily destroyed in acid solution, unstable to heat, easily lost at room temperature, and easily destroyed by visible light. Has important effect on the synthesis of protein and nucleic acid and the metabolism of various amino acids.
Biotin is a water-soluble vitamin, also belonging to the B vitamin family, B7. It is an essential substance for the synthesis of vitamin C, an indispensable substance for the normal metabolism of fats and proteins. Is a nutrient necessary for maintaining the natural growth and development of human bodies and the normal function and health of human bodies. The content of the carbon dioxide in liver, kidney, yeast and cow milk is high, and the carbon dioxide is an important factor for fixing carbon dioxide by organisms. It is easy to combine with one of chicken proteins, and the absorption of biotin can be blocked by a large amount of edible raw protein, resulting in biotin deficiency. Form the photosensitive material in visual cells, maintain the integrity and the soundness of epithelial tissue structure, enhance the immune response and the resistance of organisms, maintain normal growth and development, and can be used for treating arteriosclerosis, apoplexy, lipid metabolism disorder, hypertension, coronary heart disease and blood circulation disorder diseases.
Ferric pyrophosphate is an inorganic salt with a molecular formula of Fe4(O7P2)3. Is yellow to brown powder, and has no odor and slight iron taste. The solution was a white to pale yellow emulsion. Obtained by reacting ferric chloride solution with sodium pyrophosphate solution. Can be used as food nutrition supplement (iron fortifier) for fortifying milk powder.
Zinc oxide is an inorganic substance, has a chemical formula of ZnO, and is an oxide of zinc. Is insoluble in water and soluble in acid and strong base. Zinc oxide in food mainly acts as an additive, and zinc is an essential element for human body.
Sodium selenite is an inorganic substance with chemical formula of Na2SeO3White crystals or crystalline powders. Can be used as selenium nutrition enhancer. Selenium is a component of glutathione peroxidase, and maintains the function of cell membranes through oxidation, increasing the yield of endogenous antioxidants of the lipidic nature of proteins. Participates in energy conversion, influences metabolism, and plays an extremely important role in fat emulsification and absorption and multivitamin absorption. Meanwhile, the enzyme also participates in the synthesis of coenzyme A and coenzyme Q, and influences the functions of other biological enzyme systems. Has effects on amino acid metabolism, protein synthesis, carbohydrate metabolism, and biological oxidation.
Tricalcium phosphate is a safe nutrient supplement, is mainly added into food to strengthen the intake of calcium, and can also be used for preventing or treating the symptoms of calcium deficiency.
The maltodextrin is prepared by using various starches as raw materials, and performing low-degree controlled hydrolytic conversion, purification and drying through an enzymatic process. The raw materials are corn containing starch, rice and the like. Or refined starch such as corn starch, wheat starch, tapioca starch, etc. Maltodextrin is widely used in candy, malted milk, fruit tea, milk powder, ice cream, beverage, can and other food, and is a filling material and a blending agent for various foods. Has the characteristics of high paste viscosity, good solubility, strong thickening stability and the like, and has good intersolubility with animal glue or other vegetable glue and better combined effect.
The nutrient mixture is a mixture of the above vitamins and minerals, and the proportion of each nutrient is properly prepared according to the required amount of the old, so that the requirements of the old on the vitamins and minerals can be met, and the nutrient mixture can be independently used.
A nutritional supplement for improving muscle attenuation and delaying aging comprises the nutrient mixture, fermented pea protein peptide powder, corn oligopeptide powder, vitamin K2(1000ppm) and soybean milk powder composition.
Further, by weight, 1-1.5 parts of nutrient mixture, 0.5-1.5 parts of fermented pea protein peptide powder, 0.5-1.5 parts of corn oligopeptide powder, 0.004-0.08 part of vitamin K2(1000ppm) and 7.8-11.8 parts of soybean milk powder composition.
The fermented pea protein peptide powder is prepared by extruding and crushing pea protein powder, adding an enzyme promoter and neutral protease into the extruded pea protein powder together, and performing enzymolysis on the pea protein powder to prepare the pea protein peptide powder. The pea peptide contains 8 amino acids which can not be synthesized by human body, and has various physiological activities and functions. Researches show that pea protein polypeptide can inhibit the activity of calmodulin-dependent protein kinase to influence calcium absorption, and researches also show that the effective inhibiting component peptide of angiotensin converting enzyme can be extracted from pea peptide; the pea peptide can effectively eliminate DPPH free radicals and OH free radicals, thereby having oxidation resistance. In addition, the pea peptide also has the positive effects of lowering blood pressure, reducing blood fat, reducing cholesterol, resisting cancer, resisting fatigue, resisting aging and the like on a human body, and mainly can help to improve immunity, regulate intestines and stomach, comprehensively supplement amino acid and promote collagen synthesis. The research also finds that the compound can relieve the effects of insulin resistance and the like to a certain extent.
The corn oligopeptide powder is produced by using corn protein powder as a raw material and carrying out processes such as size mixing, protease enzymolysis, separation, filtration, spray drying and the like. The corn oligopeptide powder is a new resource product, is a mixture of various small peptides obtained by degrading corn protein through enzyme, has excellent characteristics of peptide substances, and has the functions of direct absorption superior to amino acid or protein, strong solubility (completely soluble in water under a large pH value range, no turbidity and precipitate generation), strong stability (stable to heat, unchanged components and functions), high safety (natural food protein, safety, reliability, no toxic or side effect) and the like. The antioxidant capacity is one of the important activities of the corn peptide, which is probably because the corn peptide contains certain specific amino acids with free radical scavenging and reducing capacity, such as lysine, tyrosine, phenylalanine, proline and the like, and in vitro researches show that the small-molecule corn peptide can obviously inhibit the peroxidation of cell and tissue fat, can enhance the level of reduced glutathione peroxidase, has strong scavenging effect on superoxide anion free radicals and hydroxyl free radicals, and has correlation between the capacity of scavenging superoxide anions and the capacity of scavenging hydroxyl free radicals. The corn active peptide also has the function of reducing blood pressure, and scientific researches have found that the corn oligopeptide contains a large amount of antihypertensive peptides. These peptides exert a blood pressure lowering effect by decreasing the activity of angiotensin converting enzyme in the human body. In addition, it also has physiological functions of resisting fatigue, reducing cholesterol, promoting alcohol metabolism, etc.; the corn oligopeptide has more obvious advantages, can be absorbed without gastrointestinal digestion or only needs slight digestion, has obvious advantages on gastrointestinal tract digestive function reduction of old people, has good water solubility and stability, contains a large amount of glutamic acid, and has the function of maintaining and promoting brain cell functions.
Vitamin K2 is a general name of a series of terpene side chain compounds containing 2-methyl-1, 4-naphthoquinone mother nucleus and a plurality of isoprene structural units with different numbers at C3 position, vitamin K2 is the only bioactive form of vitamin K, and is mainly used for accelerating blood coagulation, maintaining blood coagulation time and treating hemorrhage caused by vitamin K deficiency.
Further, the soymilk powder composition comprises 3.5-4.0 parts of instant soybean powder, 3.0-4.0 parts of full cream milk powder, 0.2-0.6 part of dietary fiber, 0.05-0.1 part of konjac flour, 0.01-0.04 part of momordica grosvenori powder, 0.25-0.75 part of sodium caseinate, 0.05-0.15 part of sodium hexametaphosphate, 0.025-0.075 part of trisodium phosphate, 0.05-0.10 part of tricalcium phosphate, 0.1-0.2 part of thickening agent, 0.025-0.075 part of pH regulator, 0.03-0.1 part of essence and 0.5-1.5 parts of sweetening agent.
Further, the dietary fiber is resistant dextrin; the thickening agent is at least one of xanthan gum and carrageenan; the pH regulator is sodium bicarbonate; the essence is at least one of wheat essence and milk essence; the sweetener is at least one of xylitol and stevioside.
The instant soybean powder is one of double proteins due to the characteristics of quick dissolution, easy dissolution and the like, and the instant soybean powder contains rich and high-quality vegetable protein and grease and does not contain cholesterol. It can rapidly increase the protein content; the fat in the bean powder is mainly vegetable fat, and the content of unsaturated fatty acid is high; the bean flour contains abundant dietary fiber, and can improve dyspepsia of the elderly. Has effects in reducing blood fat, reducing weight, resisting blood coagulation, resisting oxidation, resisting cancer, and regulating immunity.
The whole milk powder provides high-quality animal protein, the protein content is not lower than 24%, the whole milk powder is used as fast protein, contains 8 kinds of amino acids essential for human body, is close to the requirement of human body, has good absorption efficiency, and is matched with instant soybean powder to improve the absorption of double proteins.
The resistant dextrin is used as soluble dietary fiber formed by partial degradation and glycosylation transfer of starch, has the advantages of heat resistance, acid resistance, freezing resistance, low browning and storage resistance, does not change the quality of food when added into the food, and also has the functions of reducing blood sugar and regulating intestinal tracts. Can be added into dairy product to partially replace granulated sugar or fat and enhance dietary fiber content.
The konjac glucomannan in the konjac flour is the main nutritional ingredient of the konjac flour, and has the effects of regulating glucose metabolism and preventing and treating diabetes; regulating lipid metabolism, and preventing and treating coronary heart disease; inhibiting obesity in human body; regulating gastrointestinal tract, and preventing constipation; improving immunity, and preventing cancer.
The fructus Siraitiae Grosvenorii powder contains multiple nutrients and bioactive factors, including vitamins, trace elements, essential amino acids, flavone, polysaccharide and sweet glycoside. The momordica grosvenori can inhibit bacteria, diminish inflammation, resist tumors, regulate the immune system, prevent chronic diseases such as cardiovascular and cerebrovascular diseases and the like, can also obviously intervene abnormal glycolipid metabolism, and is widely used as a functional sweetener in the fields of foods, functional foods and special medicine foods at present. The nutritive value of the momordica grosvenori mainly comprises a medical value and a dietotherapy value. The medicinal value mainly has the effects of moistening the lung, relieving cough and constipation, and simultaneously has the novel pharmaceutical effects of enhancing resistance, resisting oxidation, protecting the liver, preventing cariogenic and the like.
Sodium caseinate is used as a food additive, can play roles of emulsification, stabilization and protein fortifier, is also a thickening agent, and is widely applied to food.
The sodium hexametaphosphate is used as a food quality modifier to protect the color and luster of the food and has uniform texture.
Trisodium phosphate is used as an emulsifier, a nutritional supplement, a quality improver in food processing. As a sodium supplement, maintain normotensive blood pressure and enhance neuromuscular excitability.
Tricalcium phosphate is a safe nutrition enhancer, is mainly added into food to enhance the intake of calcium, and can also be used for preventing or treating the symptoms of calcium deficiency; and secondly, the compound is widely applied to milk powder as a glidant.
Xanthan gum has the effect of thickening dairy products, maintaining consistency and fluidity of food appearance. The latest research finds that the xanthan gum thickener is not easy to disperse food, thereby reducing swallowing difficulty and aspiration rate, and has the function of improving swallowing function for the elderly patients with swallowing disorder.
The carrageenan and the xanthan gum play a synergistic role simultaneously, and the elasticity and the water retention of the gel are improved simultaneously.
The sodium bicarbonate can regulate the overall pH value of the formula, neutralize gastric acid, dissolve mucus, reduce the viscosity of digestive juice, strengthen the contraction of stomach and intestine, and play roles in invigorating stomach, inhibiting acid and stimulating appetite.
The wheat flavor essence is a novel flavoring agent and has strong and natural wheat flavor. The product is used in beverage, cake, bread and other products, and has the function of promoting the product fusion with milk fragrance together, and has strong appetite and comfortable sensory feeling.
The milk essence can enhance the milk flavor of the milk powder and adjust the palatability of the product.
Xylitol not only can be used as a sweetening agent and an auxiliary therapeutic agent for diabetics, but also has the following effects: preventing dental caries, preventing respiratory tract infection, preventing hyperostosis, resisting oxidation, stabilizing insulin, and regulating intestinal flora.
Stevioside is a glycoside extracted from the leaves of stevia rebaudiana Bertoni of Compositae. Stevia rebaudiana is native to paraguay and brazil, and has the characteristics of high sweetness and low heat energy, the sweetness of the stevia rebaudiana is 200-300 times that of cane sugar, the calorific value is only 1/300 of cane sugar, the stevia rebaudiana is stable in acid and salt solution, and the stevia rebaudiana is stable in nature at room temperature. Is easily dissolved in water, can quickly absorb moisture in the air, and has the solubility of over 40 percent at room temperature. Stevioside is used together with citric acid or glycine, so that the taste is good; it can be mixed with sucrose, fructose, and other sweeteners to obtain good taste. The product is not absorbed after being eaten, does not generate heat energy, and is a good natural sweetener for patients with diabetes and obesity.
The soymilk powder composition can also be the existing commercial finished soymilk powder.
The invention also provides the application of the nutritional supplement in the preparation of health products for improving the body functions of the old, the blood biochemical indexes and/or sarcopenia of the old.
Preferably, the function of improving the body function of the elderly is to improve the walking speed of the elderly.
Preferably, the biochemical index for improving the blood of the elderly people is the improvement of the 25(OH) D level and/or the serum albumin level of the elderly people.
Preferably, the sarcopenia is improved by increasing the concentration of vitamin D and albumin and reducing the concentration of serum hypersensitive C-reactive protein.
Among them, vitamin DVD affects the proliferation, differentiation, protein synthesis and contractile function of cells through 2 regulation modes of its receptor-mediated transcription factor activity and non-transcription factor activity: in one aspect, active vitamin D causes myoblast proliferation, differentiation and protein synthesis by binding to its receptor; on the other hand, active vitamin D releases calcium into the cytoplasm by activating cellular second messenger cyclic amp, diacylglycerol, inositol triphosphate, arachidonic acid or by activating protein kinase C, and activates calcium endoplasmic reticulum transport by Ca2+ atpase to increase calcium storage, promoting muscle contraction. Albumin is an important nutrient in the human body and provides the basic material for the anabolism of muscles. The hypersensitive C-reactive protein is an important chronic inflammation marker in vivo, and the IKK/NF-kB/MuRF1 signal channel activation mediated by chronic inflammation reaction can obviously influence the proliferation and differentiation functions of myoblasts and promote the catabolism of contractile proteins.
Furthermore, the dosage of the nutritional supplement is 20-30 g/day.
Compared with the prior art, the nutritional supplement and the application thereof have the following advantages:
(1) the nutritional supplement can obviously improve the walking speed (important evaluation indexes of muscle function attenuation and aging) of the old, effectively increase the 25(OH) D level and the albumin level of serum, reduce the concentration of serum hypersensitive C reactive protein, has ideal effect of improving the muscle attenuation of the old, improves the independent living capacity and the living quality of the old, delays aging and prolongs the health life;
(2) the nutritional supplement is designed aiming at the physiological characteristics and nutritional requirements of the old, is rich in protein components such as easily absorbed amino acids, peptides, high-quality proteins and the like, multiple vitamins and mineral substances, small in toxic and side effects, good in safety, remarkable in effect of improving body functions and cognitive functions, capable of being taken for a long time and good in medicinal prospect.
Drawings
FIG. 1 is an external package used for placebo control, low dose nutritional supplement intervention, and high dose nutritional supplement intervention groups;
figure 2 is a technical roadmap for the intervention study with a double-blind randomized intervention trial.
Detailed Description
Unless defined otherwise, technical terms used in the following examples have the same meanings as commonly understood by one of ordinary skill in the art to which the present invention belongs. The test reagents used in the following examples, unless otherwise specified, were all conventional biochemical reagents; the experimental methods are conventional methods unless otherwise specified.
The present invention will be described in detail below with reference to the following examples and the accompanying drawings.
1. Design of research
Double-blind randomized intervention trials.
2. Selection of study subjects: 132 elderly people with mild cognitive impairment who are 65 years old or older and do not take any nutritional supplement at present are selected as study subjects in the study, and the study subjects are audited by ethical committees and are informed to participate in the study through written consent.
3. The intervention method comprises the following steps: the subjects were randomly divided into 4 groups, blank control group, placebo control group, low dose nutritional supplement intervention group, and high dose nutritional supplement intervention group. Wherein the placebo group adopts soymilk powder placebo without other nutrients; the placebo control group, the low dose nutritional supplement intervention group, and the high dose nutritional supplement intervention group were packaged identically as shown in fig. 1. Wherein, the first and the second end of the pipe are connected with each other,
the dosage of the placebo control group is 13 g/day;
the dosage of the low-dose nutritional supplement intervention group is 13 g/day;
the dosage of the high-dose nutritional supplement intervention group is 26 g/day.
The nutritional supplement and soymilk powder placebo formulations are shown in table 1. The researchers and the study objects do not know group allocation, and the data is decoded after being analyzed. The intervention trial was carried out for 3 months.
TABLE 1 nutritional supplement and soymilk powder placebo formula
aRefer to table 2.
TABLE 2 nutrient mix formulation
4. Evaluation indexes: blood samples are collected before and after intervention, and blood biochemical indexes are measured. Measuring body function indexes such as body composition, grip strength and walking speed. The structured questionnaire was used to assess lifestyle information of the elderly such as cognitive function, dietary nutrient intake, physical activity, smoking, alcohol consumption, etc.
5. Statistical analysis methods and conclusions derived: the impact of "nutritional supplement" intervention on the physical and cognitive function of the elderly was analyzed using one-way anova, logistic regression, etc. methods for comparisons between groups. Based on the above analysis results, the effect of "nutritional supplement" intervention on the improvement of cognitive function, body composition, grip strength, walking speed and blood index of the elderly is clarified.
6. Quality control during interventions
6.1 the powder packages are randomly grouped, and the size, shape, color and smell of the powder packages in each group are the same, so that the influence of factors such as the psychology of a research object and a research executor is avoided.
6.2 telephone follow-up every two weeks, collecting compliance data and monitoring whether adverse reaction and other information exist.
7. Randomized crossover intervention trial technology roadmap
Aiming at the elderly with mild cognitive impairment above 65 years old, a random intervention test is designed, and the improvement effect of physical performance, cognitive function, blood biochemical indexes and the like of the elderly by taking the nutritional supplement is determined. FIG. 2 is a technical route of intervention research.
8. Results of the study
8.1 this study was evaluated by questionnaire and blood sample testing for baseline dietary intake, total energy intake, smoking and drinking habits, physical activity levels, and various blood indicators of the participants, and a comparison of baseline characteristic indicators among the high dose nutritional supplement intervention group, the low dose nutritional supplement intervention group, the placebo-controlled group, and the blank-controlled group is shown in Table 3. Analysis by statistical test showed that all features were not statistically different between the four groups (P >0.05) and baselines were substantially balanced and comparable between groups.
Table 3 random intervention test participants baseline characteristics table (n as 132)
8.2 before and after 3 months of intervention, the physical ability, cognitive function, serum 25(OH) D, hypersensitive C reactive protein and albumin level of the elderly are evaluated respectively, and the change of each index after the intervention is calculated, which is shown in Table 4. As can be seen from Table 4, after 3 months of intervention, the difference between groups of differences between walking speed before and after (post-intervention-pre-intervention) was statistically significant
(P <0.01), differences between groups of serum albumin pre-and post-differential (post-intervention-pre-intervention) were also statistically significant (P < 0.05). In addition, there were significant differences in changes in serum 25(OH) D
(P < 0.05). Wherein the serum 25(OH) D levels were significantly higher in the high dose nutritional supplement intervention group than in the placebo control group (P <0.01) and the blank control group (P <0.0001) after 3 months of intervention; the low dose nutritional supplement intervention group was significantly higher than the blank control group (P < 0.01).
Table 4 table of changes in physical function, cognitive function and blood index of elderly people of different groups after 3 months intervention (n ═ 132)
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (10)
1. The nutrient mixture is characterized by comprising the following components in parts by weight: 0.18-0.35 part of vitamin mixture, 0.65-1.15 parts of mineral and 0.03-0.05 part of auxiliary material.
2. The nutrient mix as claimed in claim 1, wherein the vitamin mixture comprises the following components in parts by weight: vitamin A3250.004-0.008 parts, vitamin D1000.006-0.009 parts, vitamin E0.01-0.03 parts, vitamin B10.001-0.003 parts, vitamin B20.01-0.03 parts, vitamin B60.04-0.08 parts, vitamin B120.002-0.004 parts, vitamin C0.1-0.15 parts, nicotinamide 0.008-0.012 parts, folic acid 0.0015-0.003 parts and biotin 0.003-0.005 parts.
3. The nutrient mix as claimed in claim 1, wherein the minerals comprise the following components in parts by weight: 0.06-0.1 part of ferric pyrophosphate, 0.008-0.012 part of zinc oxide, 0.015-0.02 part of sodium selenite and 0.6-1 part of tricalcium phosphate.
4. The nutrient mix as claimed in claim 1, wherein: the auxiliary material is maltodextrin.
5. A nutritional supplement for improving muscle attenuation and delaying aging, which is characterized in that: comprising the nutrient blend of any one of claims 1 to 4, fermented pea protein peptide powder, corn oligopeptide powder, vitamin K2 and soymilk powder composition.
6. The nutritional supplement for improving muscle decline and delaying aging according to claim 5, wherein: the nutrient mixture comprises, by weight, 1-1.5 parts of the nutrient mixture, 0.5-1.5 parts of the fermented pea protein peptide powder, 0.5-1.5 parts of the corn oligopeptide powder, 0.78-0.08 part of vitamin K20.004 and 7.8-11.8 parts of the soybean milk powder composition.
7. The nutritional supplement for improving muscle decline and delaying aging according to claim 6, wherein: the soymilk powder composition comprises 3.5-4.0 parts of instant soybean powder, 3.0-4.0 parts of full cream milk powder, 0.2-0.6 part of dietary fiber, 0.05-0.1 part of konjaku flour, 0.01-0.04 part of momordica grosvenori powder, 0.25-0.75 part of sodium caseinate, 0.05-0.15 part of sodium hexametaphosphate, 0.025-0.075 part of trisodium phosphate, 0.05-0.10 part of tricalcium phosphate, 0.1-0.2 part of thickening agent, 0.025-0.075 part of pH regulator, 0.03-0.1 part of essence and 0.5-1.5 parts of sweetening agent.
8. The nutritional supplement for improving muscle decline and delaying aging according to claim 7, wherein: the dietary fiber is resistant dextrin; the thickening agent is at least one of xanthan gum and carrageenan; the pH regulator is sodium bicarbonate; the essence is at least one of wheat essence and milk essence; the sweetener is at least one of xylitol and stevioside.
9. Use of the nutritional supplement according to claim 5, characterized in that: the nutritional supplement is applied to the preparation of health products for improving the body functions of the elderly, the blood biochemical indexes of the elderly and/or sarcopenia;
preferably, the function of improving the body of the old is to improve the walking speed of the old; the biochemical index for improving the blood of the elderly people is to improve the 25(OH) D level and/or the serum albumin level of the elderly people; the sarcopenia is improved by increasing the concentration of vitamin D and albumin and reducing the concentration of serum hypersensitive C reactive protein.
10. Use of the nutritional supplement according to claim 9, characterized in that: the dosage of the nutritional supplement is 20-30 g/day.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210378872.6A CN114680339A (en) | 2022-04-12 | 2022-04-12 | Nutritional supplement for improving muscle attenuation and delaying senescence and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210378872.6A CN114680339A (en) | 2022-04-12 | 2022-04-12 | Nutritional supplement for improving muscle attenuation and delaying senescence and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114680339A true CN114680339A (en) | 2022-07-01 |
Family
ID=82143821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210378872.6A Pending CN114680339A (en) | 2022-04-12 | 2022-04-12 | Nutritional supplement for improving muscle attenuation and delaying senescence and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114680339A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115918914A (en) * | 2022-12-01 | 2023-04-07 | 宝健(北京)生物技术有限公司 | Oral nutritional supplement containing compound protein, preparation and application |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106072573A (en) * | 2016-07-05 | 2016-11-09 | 郑州和正生物科技有限公司 | A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible |
CN107712059A (en) * | 2017-10-30 | 2018-02-23 | 诺和生物技术(天津)有限公司 | A kind of nutrient formulation powder for suitably increasing the elderly's muscle and preparation method thereof |
CN107821602A (en) * | 2017-10-30 | 2018-03-23 | 诺和生物技术(天津)有限公司 | Nutrient formulation powder that a kind of suitable muscle decay crowd eats and preparation method thereof |
CN107927797A (en) * | 2017-12-11 | 2018-04-20 | 重庆市生物技术研究所有限责任公司 | It is a kind of to eat the wholefood formula containing small peptide for muscle decay syndrome crowd |
CN108095072A (en) * | 2017-12-11 | 2018-06-01 | 重庆市生物技术研究所有限责任公司 | Small peptide spy's dietary seafood formula is eaten for long-term bed and muscle attenuation syndrome crowd |
CN108618129A (en) * | 2018-05-10 | 2018-10-09 | 上海奥医生物医药科技有限公司 | Sarcopenia tailored version clinical nutrition formula and preparation method thereof |
CN109077302A (en) * | 2018-07-18 | 2018-12-25 | 辰欣药业股份有限公司 | A kind of medical food and preparation method thereof treating and preventing old aged muscle decaying syndrome |
CN109588709A (en) * | 2018-12-04 | 2019-04-09 | 沈阳师范大学 | A kind of compound protein powder and preparation method preventing old aged muscle decaying |
CN111972672A (en) * | 2020-08-25 | 2020-11-24 | 黑龙江省完达山乳业股份有限公司 | Composition with muscle increasing function and application thereof |
CN112715961A (en) * | 2020-12-29 | 2021-04-30 | 北京康比特体育科技股份有限公司 | Food composition for promoting muscle growth of elderly diabetic patients |
CN115444129A (en) * | 2022-09-09 | 2022-12-09 | 谢琪 | Nutritional functional food formula for sarcopenia and preparation method thereof |
-
2022
- 2022-04-12 CN CN202210378872.6A patent/CN114680339A/en active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106072573A (en) * | 2016-07-05 | 2016-11-09 | 郑州和正生物科技有限公司 | A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible |
CN107712059A (en) * | 2017-10-30 | 2018-02-23 | 诺和生物技术(天津)有限公司 | A kind of nutrient formulation powder for suitably increasing the elderly's muscle and preparation method thereof |
CN107821602A (en) * | 2017-10-30 | 2018-03-23 | 诺和生物技术(天津)有限公司 | Nutrient formulation powder that a kind of suitable muscle decay crowd eats and preparation method thereof |
CN107927797A (en) * | 2017-12-11 | 2018-04-20 | 重庆市生物技术研究所有限责任公司 | It is a kind of to eat the wholefood formula containing small peptide for muscle decay syndrome crowd |
CN108095072A (en) * | 2017-12-11 | 2018-06-01 | 重庆市生物技术研究所有限责任公司 | Small peptide spy's dietary seafood formula is eaten for long-term bed and muscle attenuation syndrome crowd |
CN108618129A (en) * | 2018-05-10 | 2018-10-09 | 上海奥医生物医药科技有限公司 | Sarcopenia tailored version clinical nutrition formula and preparation method thereof |
CN109077302A (en) * | 2018-07-18 | 2018-12-25 | 辰欣药业股份有限公司 | A kind of medical food and preparation method thereof treating and preventing old aged muscle decaying syndrome |
CN109588709A (en) * | 2018-12-04 | 2019-04-09 | 沈阳师范大学 | A kind of compound protein powder and preparation method preventing old aged muscle decaying |
CN111972672A (en) * | 2020-08-25 | 2020-11-24 | 黑龙江省完达山乳业股份有限公司 | Composition with muscle increasing function and application thereof |
CN112715961A (en) * | 2020-12-29 | 2021-04-30 | 北京康比特体育科技股份有限公司 | Food composition for promoting muscle growth of elderly diabetic patients |
CN115444129A (en) * | 2022-09-09 | 2022-12-09 | 谢琪 | Nutritional functional food formula for sarcopenia and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
马莹;: "老年人营养需求及膳食对策", 中国食物与营养, no. 04, pages 79 - 81 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115918914A (en) * | 2022-12-01 | 2023-04-07 | 宝健(北京)生物技术有限公司 | Oral nutritional supplement containing compound protein, preparation and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111528483A (en) | Functional meal replacement powder with balanced nutrition and preparation method thereof | |
CA2648653C (en) | Fat accumulation inhibitor | |
EP1797891A1 (en) | Total enteral nutritious composition | |
CN104544432A (en) | Samara oil compound protein solid beverage and method for preparing same | |
JPH09191852A (en) | Healthy food | |
WO2008014674A1 (en) | A nutritional and health-care edible potassium salt with wide purpose | |
CN111802476A (en) | Milk powder for improving sleep quality of children and preparation method thereof | |
KR101896024B1 (en) | Functional food compositions comprising extracts of Garcinia Cambogia as active ingredients and method for preparing the same | |
CN101569410A (en) | Special meal nutritional foods used by tumor patients | |
KR101356330B1 (en) | Hepatic function remedial agent | |
JPH0920660A (en) | Stress-resistant composition | |
CN1127070A (en) | Healthful nutrition milk powder and production method | |
US20200155589A1 (en) | Composition For Enchanced Recovery After Surgery (ERAS) | |
CN114680339A (en) | Nutritional supplement for improving muscle attenuation and delaying senescence and application thereof | |
KR20110119305A (en) | A functional beverage comprising taurine, royal jelly, red ginseng, lycii fructus, glumate and apple essence as main ingredients | |
EP1656943A1 (en) | Extract from plant of japanese parsley family and process for producing the same | |
KR101540004B1 (en) | Composition of Health Functional Foods for Improving of Blood sugar, Blood pressure, Blood Circulation and Cholesterol into Blood | |
CN110584120A (en) | Bone health composition | |
US20100197611A1 (en) | Alternative agent with vitamin d-like activity and an improving agent for intestinal function | |
JP2006199641A (en) | Iron-adsorbing polymer substance, iron-containing polymer substance and method for producing the same | |
KR100734944B1 (en) | Functional food-composition with calcium lactate and rice bran | |
KR100515923B1 (en) | The bio conjugated proteins is process of produce | |
CN115886171B (en) | Composite solid beverage and preparation method thereof | |
KR102502112B1 (en) | Composition and health functional food containing Lactococcus lactis IDCC 2301 having vitamin C production ability | |
KR102532514B1 (en) | A composition for ameliorating hangover comprising Fagopyrum tataricum extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |